Automate Your Wheel Strategy on GMAB
With Tiblio's Option Bot, you can configure your own wheel strategy including GMAB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GMAB
- Rev/Share 23.2421
- Book/Share 60.3397
- PB 3.0745
- Debt/Equity 0.9509
- CurrentRatio 2.0217
- ROIC 0.0466
- MktCap 114315277543.2708
- FreeCF/Share 7.2074
- PFCF 25.7402
- PE 39.1189
- Debt/Assets 0.4319
- DivYield 0
- ROE 0.1061
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | GMAB | Morgan Stanley | -- | Equal Weight | -- | $34 | Feb. 17, 2026 |
| Resumed | GMAB | Jefferies | -- | Buy | -- | $41.5 | Feb. 17, 2026 |
| Upgrade | GMAB | Guggenheim | Neutral | Buy | -- | $43 | Sept. 23, 2025 |
| Downgrade | GMAB | Bernstein | Market Perform | Underperform | -- | -- | April 1, 2025 |
| Upgrade | GMAB | William Blair | Market Perform | Outperform | -- | -- | March 11, 2025 |
| Upgrade | GMAB | Leerink Partners | Market Perform | Outperform | -- | $27 | Feb. 13, 2025 |
| Initiation | GMAB | Redburn Atlantic | -- | Buy | -- | -- | Oct. 8, 2024 |
| Resumed | GMAB | Morgan Stanley | -- | Equal Weight | -- | $31 | Sept. 4, 2024 |
| Downgrade | GMAB | JP Morgan | Overweight | Neutral | -- | -- | Aug. 20, 2024 |
News
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Published: February 24, 2026 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; February 24, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 12,313 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others.
Read More
Transactions in Connection with Share Buy-back Program
Published: February 23, 2026 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; February 23, 2026 – Genmab A/S (Nasdaq: GMAB). On February 17, 2026, Genmab announced the initiation of a share buy-back program to repurchase up to 342,130 shares with a maximum aggregate total value of DKK 725 million to honor our commitments under the Restricted Stock Unit program.
Read More
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Published: February 20, 2026 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; February 20, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.
Read More
Notice to Convene the Annual General Meeting of Genmab A/S
Published: February 18, 2026 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement Genmab A/S to hold Annual General Meeting on Thursday March 19, 2026 COPENHAGEN, Denmark; February 18, 2026 – Genmab A/S (Nasdaq: GMAB) summons the Annual General Meeting on Thursday, March 19, 2026, at 2:00 PM CET at the Copenhagen Marriott Hotel, Kalvebod Brygge 5, DK-1560 Copenhagen V, Denmark. The notice for the Annual General Meeting, including Appendix 1: Candidates for the Board of Directors, is attached.
Read More
Genmab Announces Initiation of Share Buy-Back Program
Published: February 17, 2026 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement Repurchase of up to 342,130 shares with a maximum aggregate total value of 725 million DKK Honoring our commitments under the Restricted Stock Unit program Completion expected no later than March 31, 2026 COPENHAGEN, Denmark; February 17, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that it is initiating a share buy-back program, to honor our commitments under the Restricted Stock Unit program. The share buy-back program will be undertaken on the terms set out below and in accordance with Regulation (EU) No.
Read More
Genmab Files Annual Report with the U.S. Securities and Exchange Commission
Published: February 17, 2026 by: GlobeNewsWire
Sentiment: Neutral
Media Release COPENHAGEN, Denmark; February 17, 2026 Genmab filed Form 20-F for the financial year 2025 with the U.S. SEC Genmab A/S (Nasdaq: GMAB ) a nnounced today that it has filed its Annual Report for the financial year 2025 on Form 20-F with the U.S. Securities and Exchange Commission (SEC), incorporating by reference parts of the Genmab A/S Annual Report 2025. Both reports are available via the SEC's website, www.sec.gov and Genmab's website, www.genmab.com.
Read More
Genmab Publishes 2025 Annual Report
Published: February 17, 2026 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; February 17, 2026 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2025. Below is a summary of business progress in 2025, financial performance for the year and the financial outlook for 2026.
Read More
Is the Options Market Predicting a Spike in Genmab Stock?
Published: February 13, 2026 by: Zacks Investment Research
Sentiment: Neutral
Investors need to pay close attention to GMAB stock based on the movements in the options market lately.
Read More
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Published: January 29, 2026 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; January 29, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 32,806 restricted stock units and 34,307 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1.
Read More
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Published: January 16, 2026 by: Business Wire
Sentiment: Neutral
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, which demonstrated an improvement in progression-free survival (PFS) (HR: 0.74 [95% CI 0.60 to 0.92])* in patients treated with epcoritamab monotherapy. Additionally, improvements were observed in the complete response rate, duration of response, and time to next treatment.
Read More
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Published: January 16, 2026 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement Based on the topline results from the EPCORE ® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss next steps COPENHAGEN, Denmark; January 16, 2026 – Genmab A/S (Nasdaq: GMAB) today announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, which demonstrated an improvement in progression-free survival (PFS) (HR: 0.74 [95% CI 0.60 to 0.92])* in patients treated with epcoritamab monotherapy. Additionally, improvements were observed in the complete response rate, duration of response, and time to next treatment among patients treated with epcoritamab monotherapy.
Read More
Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence
Published: January 07, 2026 by: GlobeNewsWire
Sentiment: Neutral
Media Release COPENHAGEN, Denmark; January 07, 2026 Supports Genmab's ambition to build an AI-enabled innovation model that advances the company's vision of bringing transformative antibody medicines to patients Genmab A/S (Nasdaq: GMAB ) a nnounced today a partnership with Anthropic to advance and enhance the company's r esearch and d evelopment (R&D) processes through the adoption of cutting-edge artificial intelligence (AI) capabilities . Under the agreement, Genmab and Anthropic will design and deploy custom, Claude-powered agentic AI solutions to support Genmab's clinical development priorities.
Read More
Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence
Published: January 07, 2026 by: Business Wire
Sentiment: Neutral
COPENHAGEN, Denmark--(BUSINESS WIRE)-- #AI--Genmab has partnered with Anthropic to advance its research and development (R&D) processes through the adoption of agentic AI capabilities.
Read More
Genmab scraps development of experimental cancer therapy
Published: December 29, 2025 by: Reuters
Sentiment: Negative
Genmab will stop development of its experimental antibody therapy to treat cancer that was in late-stage trials, the Danish drugmaker said on Monday.
Read More
Genmab A/S (GMAB) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Published: December 04, 2025 by: Seeking Alpha
Sentiment: Neutral
Genmab A/S (GMAB) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Read More
Genmab Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes
Published: December 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
Media Release COPENHAGEN, Denmark; December 3, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it and its wholly owned subsidiary Genmab Finance LLC (“Genmab Finance”) have closed their previously announced offering of $1.5 billion of 6.250% senior secured notes due 2032 (the “Secured Notes”) and $1.0 billion of 7.250% senior unsecured notes due 2033 (the “Unsecured Notes,” and together with the Secured Notes, the “Notes”). Genmab intends to use the net proceeds from this offering of the Notes, together with borrowings under the new $2.0 billion senior secured term loan “B” facility, the $1.0 billion senior secured term loan …
Read More
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Published: November 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; November 20, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 6,933 restricted stock units and 7,377 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1.
Read More
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Published: November 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; November 19, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.
Read More
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Published: November 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; November 18, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 32,059 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others.
Read More
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma
Published: November 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
COPENHAGEN, Denmark; November 18, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that EPKINLY® (epcoritamab-bysp) in combination with rituximab and lenalidomide (EPKINLY + R2) was approved by the U.S. Food and Drug Administration (FDA) for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on results from the pivotal Phase 3 EPCORE® FL-1 study that evaluated fixed duration EPKINLY + R2 compared to standard of care R2.i
Read More
Genmab Provides Certain Information Disclosed in Connection with Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes
Published: November 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
Media Release COPENHAGEN, Denmark; November 10, 2025 Genmab A/S (“Genmab”) announced on November 10, 2025, that it and its wholly owned subsidiary Genmab Finance LLC intend to offer, subject to market and other conditions, $1.5 billion of senior secured notes due 2032 (the “Secured Notes”) and $1.0 billion of senior unsecured notes due 2033 (the “Unsecured Notes,” and together with the Secured Notes, the “Notes”). Genmab also launched the syndication of a new $2.0 billion senior secured term loan “B” facility, which term loan “B” facility is in addition to a $1.0 billion senior secured term loan “A” facility and …
Read More
Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting
Published: November 03, 2025 by: Business Wire
Sentiment: Neutral
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced that more than 20 abstracts evaluating epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, across lines of therapy and B-cell non-Hodgkin's lymphoma (NHL) subtypes, will be presented at the 67th Annual Meeting and Exposition of the American Society of Hematology (ASH), in Orlando, Florida, and online, December 6-9. Data from the epcoritamab development program will showcase its expan.
Read More
Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting
Published: November 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
Media Release COPENHAGEN, Denmark; November 3, 2025 More than 20 abstracts, including seven oral presentations, highlight advancements from the epcoritamab development program supporting the expanded clinical profile and potential of epcoritamab for a broader range of B-cell malignancies New data demonstrate potential of epcoritamab in first and second-line settings in follicular lymphoma (FL) and first-line in diffuse large B-cell lymphoma (DLBCL) Results from Phase 3 EPCORE FL-1 trial, evaluating epcoritamab in combination with rituximab and lenalidomide (R 2 ) in patients with relapsed or refractory (R/R) follicular lymphoma (FL) accepted for oral presentation Genmab A/S (Nasdaq: GMAB ) today announced …
Read More
Merus Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS
Published: October 23, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Merus N.V. (NasdaqGM: MRUS) to Genmab A/S (NasdaqGS: GMAB). Under the terms of the proposed transaction, shareholders of Merus will receive $97.00 in cash for each share of Merus that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whe.
Read More
GMAB or TECH: Which Is the Better Value Stock Right Now?
Published: October 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Genmab A/S Sponsored ADR (GMAB) and Techne (TECH). But which of these two stocks is more attractive to value investors?
Read More
GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Genmab stock surges 21.9% after striking an $8 billion deal to buy Merus, adding a late-stage cancer treatment candidate to its proprietary oncology pipeline.
Read More
What Makes Genmab A/S Sponsored ADR (GMAB) a Strong Momentum Stock: Buy Now?
Published: October 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Genmab A/S Sponsored ADR (GMAB) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Best Momentum Stock to Buy for October 3rd
Published: October 03, 2025 by: Zacks Investment Research
Sentiment: Positive
GFI, GMAB and AEG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 3, 2025.
Read More
New Strong Buy Stocks for October 3rd
Published: October 03, 2025 by: Zacks Investment Research
Sentiment: Positive
DORM, AEG, GMAB, SCSC and GFI have been added to the Zacks Rank #1 (Strong Buy) List on October 3rd, 2025.
Read More
Major Shareholder Announcement
Published: September 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; September 23, 2025 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment Management Limited has informed us that, as of September 19, 2025, Orbis Investment Management Limited through shares and ADRs, representing shares, controlled the voting rights to 3,230,732 shares in Genmab A/S, which amounts to 5.03% of the share capital and voting rights in Genmab A/S. The major shareholder announcement of Orbis Investment Management Limited is attached to this announcement.
Read More
About Genmab A/S (GMAB)
- IPO Date 2009-06-01
- Website https://www.genmab.com
- Industry Biotechnology
- CEO Jan van de Winkel
- Employees 2638